Abiopharma

🔍 Carrico Brian Allen (Director)

Company: Neuraxis, INC (NRXS)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Acquired 199,188 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: A | equity_swap_involved: 0 | shares_owned_after: 227,336.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 320,000 shares of Stock Options (Derivative)
  Date: 2026-08-24 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Acquired 0 shares of RSU (Derivative)
  Date: 2026-08-24 | Code: A | equity_swap_involved: 0 | shares_owned_after: 320,000.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F2
• Sold 0 shares of RSU (Derivative)
  Date: 2026-08-24 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F2

Footnotes:

• F1: Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.
• F2: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.